Research Funding for Deadly Cancers Falls Short, Data Reveals

Research into some of the deadliest common cancers is severely underfunded, receiving less than a fifth of total cancer research funding despite accounting for nearly 40% of cancer-related deaths, according to new data. The figures, obtained through a Freedom of Information request by the Less Survivable Cancers Taskforce (LSCT), reveal that cancers of the brain, liver, lung, oesophagus, pancreas, and stomach collectively receive merely 18.9% of all government-funded cancer research.

This disparity translates to a funding shortfall of approximately £130 less per death for these cancers compared to the average funding across all cancer types. For instance, oesophageal cancer receives as little as £40 per death, starkly contrasted with the average figure of £310.

Calls for Action from the Less Survivable Cancers Taskforce

The LSCT has highlighted this “stark imbalance” in funding as a critical factor contributing to poorer patient outcomes. The taskforce is urging the Government to reevaluate current funding models to address these discrepancies. Lorraine Dallas, chair of the LSCT Scotland group, emphasized that improving cancer survival rates in Scotland hinges on targeting less survivable cancers. She noted, “This data underlines the critical need for urgent action.”

Dallas pointed out that Scotland has pioneered initiatives aimed at early diagnosis and improved surveillance. Yet, she insists there is a pressing need for further advancements. “We want the next Scottish Government to commit to addressing the research gap,” she added, “ensuring that all patients, regardless of cancer type, have the best possible chance of survival.”

The LSCT’s call for increased investment is underscored by alarming statistics. More than 95,000 individuals in the UK are diagnosed with one of these less survivable cancers annually. As reported by the taskforce last year, over half (61%) of those diagnosed with one of the six cancers will die from their disease within 12 months.

Personal Stories Highlight Urgency for Research

The impact of these statistics is palpable, as evidenced by the experiences of patients like Amy McNamara. Diagnosed with a high-grade brain tumour known as an astrocytoma in July 2023, McNamara’s situation is compounded by the loss of two family friends to similar conditions. Following surgery and extensive treatment, she is now under active surveillance with three-monthly scans.

Reflecting on her experience, McNamara stated, “Although I’m so glad most of my tumour was removed, it’s tough to know that some of it was, and is, still here.” She expressed concern over the urgent need for increased research into brain tumours, given the high rates of diagnosis and the poor survival statistics. “These are terrifying statistics to look at, whether you are someone personally diagnosed or if it’s a family member or friend,” she remarked.

The LSCT is hosting an event for Members of the Scottish Parliament (MSPs) at Holyrood as part of Less Survivable Cancers Awareness Week. Dame Jackie Baillie, Labour’s health spokesperson, reinforced the need for prioritizing research into these cancers, stating, “If we’re going to improve outcomes for people diagnosed with these devastating diseases, then we must prioritise research into improving diagnosis and treatments that can truly make a difference.”

The Scottish Government has been approached for comment regarding these pressing issues. The LSCT’s findings underline a significant gap in cancer research funding that necessitates immediate attention to enhance patient outcomes for some of the most lethal cancers.